These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21258007)

  • 1. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism.
    Leveson-Gower DB; Olson JA; Sega EI; Luong RH; Baker J; Zeiser R; Negrin RS
    Blood; 2011 Mar; 117(11):3220-9. PubMed ID: 21258007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
    Pillai AB; George TI; Dutt S; Strober S
    Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells.
    Kuwatani M; Ikarashi Y; Iizuka A; Kawakami C; Quinn G; Heike Y; Yoshida M; Asaka M; Takaue Y; Wakasugi H
    Immunol Lett; 2006 Jul; 106(1):82-90. PubMed ID: 16806496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.
    Schneidawind D; Pierini A; Alvarez M; Pan Y; Baker J; Buechele C; Luong RH; Meyer EH; Negrin RS
    Blood; 2014 Nov; 124(22):3320-8. PubMed ID: 25293774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
    Olson JA; Leveson-Gower DB; Gill S; Baker J; Beilhack A; Negrin RS
    Blood; 2010 May; 115(21):4293-301. PubMed ID: 20233969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
    Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
    Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
    Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
    J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4.
    Kim JH; Choi EY; Chung DH
    J Immunol; 2007 Nov; 179(10):6579-87. PubMed ID: 17982047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
    Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
    Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants.
    Hongo D; Tang X; Dutt S; Nador RG; Strober S
    Blood; 2012 Feb; 119(6):1581-9. PubMed ID: 22174155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production.
    Baker J; Verneris MR; Ito M; Shizuru JA; Negrin RS
    Blood; 2001 May; 97(10):2923-31. PubMed ID: 11342413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NKT cells, Treg, and their interactions in bone marrow transplantation.
    Kohrt HE; Pillai AB; Lowsky R; Strober S
    Eur J Immunol; 2010 Jul; 40(7):1862-9. PubMed ID: 20583031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.
    Pierini A; Strober W; Moffett C; Baker J; Nishikii H; Alvarez M; Pan Y; Schneidawind D; Meyer E; Negrin RS
    Blood; 2016 Aug; 128(6):866-71. PubMed ID: 27365424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
    Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
    Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells.
    Hashimoto D; Asakura S; Miyake S; Yamamura T; Van Kaer L; Liu C; Tanimoto M; Teshima T
    J Immunol; 2005 Jan; 174(1):551-6. PubMed ID: 15611282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease.
    Du W; Leigh ND; Bian G; O'Neill RE; Mei L; Qiu J; Chen GL; Hahn T; Liu H; McCarthy PL; Cao X
    J Immunol; 2015 Nov; 195(9):4514-23. PubMed ID: 26392464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD management.
    Avivi I; Stroopinsky D; Rowe JM; Katz T
    Transpl Immunol; 2013 Jan; 28(1):57-61. PubMed ID: 23196257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells.
    Wang MG; Szebeni J; Pearson DA; Szot GL; Sykes M
    Transplantation; 1995 Sep; 60(5):481-90. PubMed ID: 7676498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.